Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Nuformix (NFX)

Price 0.19p on 29-03-2024 at 13:00:30
Change 0.00p 0%
Buy 0.20p
Sell 0.18p
Buy / Sell NFX Shares
Last Trade: -
Day's Volume: 0
Last Close: 0.19p
Open: 0.00p
ISIN: GB00BYW79Y38
Day's Range 0.00p - 0.00p
52wk Range: 0.19p - 0.44p
Market Capitalisation: £2m
VWAP: 0.00p
Shares in Issue: 819m

Recent Trades History Nuformix (NFX)

Buy/Sell Volume Trade Prc Trade Type Trade Time

Share Price History for Nuformix

Time period:
to
Date Open High Low Close Volume

Share News for Nuformix

UK shareholder meetings calendar - next 7 days

12th Mar 2024 14:30

Read More

IN BRIEF: Nuformix announces subscription to raise GBP150,000

1st Mar 2024 10:31

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Announce intention to raise gross proceeds of GBP150,000 through a subscription for 75.0 million new shares at a price of 0.20 pence each. The shares will represent 9.2% of Nuformix's enlarged issued share capital. Company will use the subscription's net proceeds primarily to further advance its NXP002 programme for the inhaled treatment of idiopathic pulmonary fibrosis. Read More

IN BRIEF: Nuformix narrows annual loss as develops drug assets

3rd Jan 2024 10:16

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses. Read More

Nuformix gets patent in Japan for pulmonary fibrosis treatment NXP002

23rd Oct 2023 12:38

(Alliance News) - Nuformix PLC on Monday said it has been issued with a patent in Japan for NXP002, its potential novel inhaled treatment for idiopathic pulmonary fibrosis. Read More

IN BRIEF: Nuformix to receive milestone payments from Oxilio pact

18th Sep 2023 10:20

Nuformix PLC - London-based pharmaceutical development company targeting unmet medical needs in fibrosis and oncology - Says it will receive immediate and near-term milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd. Nuformix does not disclose any financial details on this. Under the revised agreement, says Oxilio will acquire ownership of Nuformix's NXP001 patent estate. Says it will receive the additional milestone payments while retaining further development milestones and royalties capped at GBP2 million per year. Read More

FTSE 100 Latest
Value7,952.62
Change0.00

Login to your account

Forgot Password?

Not Registered